Key stats
About China Univ Hang Seng Hong Kong-Listed Biotech IDX ETF
Home page
Inception date
May 7, 2022
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Primary advisor
China Universal Fund Management Co. Ltd.
ISIN
CNE100005C44
Tightly track the target index, and pursue the minimization of tracking deviation and tracking err.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks97.96%
Health Technology85.54%
Distribution Services4.68%
Consumer Non-Durables3.61%
Technology Services1.85%
Commercial Services1.33%
Health Services0.92%
Retail Trade0.01%
Bonds, Cash & Other2.04%
Cash2.04%
Stock breakdown by region
Asia90.72%
Europe9.28%
North America0.00%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
513280 invests in stocks. The fund's major sectors are Health Technology, with 85.54% stocks, and Distribution Services, with 4.68% of the basket. The assets are mostly located in the Asia region.
513280 top holdings are Wuxi Biologics (Cayman) Inc. and BeOne Medicines Ltd., occupying 10.26% and 9.09% of the portfolio correspondingly.
No, 513280 doesn't pay dividends to its holders.
513280 shares are issued by China Universal Asset Management Co., Ltd. under the brand China Universal. The ETF was launched on May 7, 2022, and its management style is Passive.
513280 expense ratio is 0.20% meaning you'd have to pay 0.20% of your investment to help manage the fund.
513280 follows the Hang Seng Biotech Index - HKD - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
513280 invests in stocks.